Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 7/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 7/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 7/20 | 0.50 |
| ▸ | PTGIR | P43119 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.40 |
| ▸ | ITGAV | P06756 | 5/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.39 |
| ▸ | ME2 | P23368 | 1/20 | 0.39 |
| ▸ | ME1 | P48163 | 1/20 | 0.39 |
| ▸ | ME3 | Q16798 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6157746 | 0.94 | ADRA2A (0.53) | ADRA2AADRA2BADRA2CPTGIRITGB3 | |
| SCHEMBL6159519 | 0.87 | ADRA2A (0.57) | ADRA2AADRA2BADRA2CPTGIRL3MBTL1 | |
| SCHEMBL6158135 | 0.86 | ADRA2A (0.54) | ADRA2AADRA2BADRA2CPTGIRITGB3 | |
| SCHEMBL6159692 | 0.85 | ADRA2A (0.59) | ADRA2AADRA2BADRA2CPTGIRL3MBTL1 | |
| SCHEMBL6160595 | 0.82 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CPTGIRAOC3 | |
| SCHEMBL6159160 | 0.82 | ADRA2A (0.47) | ADRA2AADRA2BADRA2CPTGIRITGB3 | |
| SCHEMBL6159235 | 0.82 | ADRA2A (0.57) | ADRA2AADRA2BADRA2CPTGIRAOC3 | |
| SCHEMBL6158508 | 0.82 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CPTGIRAOC3 | |
| SCHEMBL6056621 | 0.81 | ADRA2A (0.45) | ADRA2AADRA2BADRA2CPTGIRITGB3 | |
| Hydrochloric Acid SCHEMBL6161439 | 0.81 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CPTGIRAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339694-B1 | SUBSTITUTED 2-PHENYLAMINOIMIDAZOLINE PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-09-21 | — | — | EP | disclosed |
| EP-1339694-A1 | SUBSTITUTED 2-PHENYLAMINOIMIDAZOLINE PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| US-20020091147-A1 | SUBSTITUTED-PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | SYNTEX (U.S.A.) LLC | 2002-07-11 | — | — | US | disclosed |
| US-6417186-B1 | TREATING PAIN, URINARY TRACT INFECTIONS, INFLAMMATION, RESPIRATORY DISEASE STATES FROM ALLERGIES OR ASTHMA, EDEMA FORMATION OR HYPOTENSIVE VASCULAR DISEASES. | SYNTEX (U.S.A.) LLC | 2002-07-09 | — | — | US | disclosed |
| WO-2002040453-A1 | SUBSTITUTED 2-PHENYLAMINOIMIDAZOLINE PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091147-A1 | SUBSTITUTED-PHENYL KETONE DERIVATIVES AS IP ANTAGONISTS | PTGER1, FFAR1, BDKRB1 | ADRA2A 50/4885ADRA2B 46/4885ADRA2C 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.